Investor Centre

Clinicians to Speak About Pharmaxis Programs

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) will host R&D showcase webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs will be followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers.

Pharmaxis drug PXS-5505 targeting several cancers:

Date & time: 29 March 2022 at 11.00am (AEDT)

Speakers:

• Myelofibrosis - Dr Gabriela Hobbs, Assistant Professor, Medicine, Harvard Medical School & Clinical Director, Leukaemia, Massachusetts General Hospital
• Hepatocellular carcinoma - Dr Paul Burchard, University of Rochester
• Pancreatic cancer - Dr Tom Cox, A/Prof School of Clinical Medicine, UNSW Sydney, Laboratory Head - Matrix and Metastasis, Garvan Institute of Medical Research

To register for this event please use the following link: https://zoom.us/webinar/register/WN_B8Te020aTUqyb2A3H93saA

 Pharmaxis drug PXS-6302 targeting scarring:

Date & time: 31 March 2022 at 11.00am (AEDT)

Speakers:

• The science of scarring and potential for LOX inhibition - Dr. Mark Fear, Senior Research Fellow University of Western Australia
• Clinical applications for LOX inhibition, unmet need and clinical development strategy - Professor Fiona Wood AM, Director of the Burn Injury Research Unit University of Western Australia

To register for this event please use the following link: https://zoom.us/webinar/register/WN_66zxZbVsRm-GCocT8_NiAQ

 The webinars are free to attend and a recording of the events will be made available on the Pharmaxis website.